Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

盘前交易 01-15 05:30:19 EST

34.34

+3.65

+11.89%

盘前35.17

+0.83+2.42%

05:27 EST

最高36.00	最低30.56	成交量688.67万
今开30.69	昨收30.69	日振幅17.73%
总市值38.82亿	流通市值37.77亿	总股本1.13亿
成交额2.33亿	换手率6.26%	流通股本1.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":34.34,"timestamp":1768424400000,"preClose":30.69,"halted":0,"volume":6886681,"hourTrading":{"tag":"盘前","latestPrice":35.17,"preClose":34.34,"latestTime":"05:27 EST","volume":189,"amount":6639.979752,"timestamp":1768472849625},"delay":0,"changeRate":0.1189312479635061,"floatShares":109980302,"shares":113036344,"eps":-2.119536,"marketStatus":"盘前交易","change":3.65,"latestTime":"01-15 05:30:19 EST","open":30.69,"high":36,"low":30.56,"amount":233202163.63318,"amplitude":0.177256,"askPrice":35.5,"askSize":88,"bidPrice":35.05,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.119536,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768487400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":34.34,"preHourTrading":{"tag":"盘前","latestPrice":35.17,"preClose":34.34,"latestTime":"05:27 EST","volume":189,"amount":6639.979752,"timestamp":1768472849625},"postHourTrading":{"tag":"盘后","latestPrice":34.5,"preClose":34.34,"latestTime":"19:59 EST","volume":89235,"amount":3066233.089,"timestamp":1768438764148},"volumeRatio":1.931688006060448,"optionData":{"bulkOrders":[{"symbol":"VKTX","call":true,"expireDate":1771563600000,"strike":"50.0","timestamp":1768420414302,"price":0.83,"volume":2000,"amount":166000,"type":"-"},{"symbol":"VKTX","call":true,"expireDate":1771563600000,"strike":"45.0","timestamp":1768420414302,"price":1.48,"volume":2000,"amount":296000,"type":"+"}]},"impliedVol":0.9135,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"2603646052","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大涨5.05%报32.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603646052","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603646052?lang=zh_cn&edition=full","pubTime":"2026-01-15 00:02","pubTimestamp":1768406550,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日00时02分，Viking Therapeutics, Inc.股票出现异动，股价急速拉升5.05%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115000231a4c3ef1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115000231a4c3ef1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4539","LENZ","BK4599","VKTX","BK4007","BK4139"],"gpt_icon":0},{"id":"1149539645","title":"Viking Therapeutics公布双靶点激动剂VK2735二期临床试验结果 获《肥胖》期刊刊载","url":"https://stock-news.laohu8.com/highlight/detail?id=1149539645","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149539645?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:04","pubTimestamp":1768219466,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.（纳斯达克代码：VKTX）近日宣布，其研发的双重GLP-1/GIP受体激动剂VK2735的二期VENTURE临床试验结果，已正式发表于国际权威期刊《肥胖》（Obesity）。该研究针对肥胖症患者展开，数据显示VK2735在体重管理方面展现出显著疗效与良好安全性。\n此次发表标志着VK2735的临床数据获得学术界的专业认可，为后续研发及商业化进程提供了重要科学依据。公司表示将继续推进该药物的临床开发，探索其在代谢疾病治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4599","BK4139","VKTX"],"gpt_icon":0},{"id":"1126995143","title":"Viking Therapeutics宣布完成VK2735肥胖维持剂量临床试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1126995143","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126995143?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:13","pubTimestamp":1767874431,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc. (VKTX) 已正式完成其候选药物VK2735针对肥胖症的维持剂量临床试验患者招募工作。该里程碑标志着该药物研发项目进入关键新阶段，为后续疗效数据分析奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4139","BK4588","BK4585","BK4599"],"gpt_icon":0},{"id":"1149069374","title":"诺和诺德减肥药Wegovy新版药片已上市，竞争对手Lilly和Viking股票反应如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=1149069374","media":"老虎资讯综合","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149069374?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:22","pubTimestamp":1767691330,"startTime":"0","endTime":"0","summary":"诺和诺德旗下大获成功的肥胖治疗药物现已推出口服剂型，成为美国首个用于减重的GLP-1口服药物。该口服药提供四种剂量规格，价格低于注射版Wegovy。针对拥有商业健康保险的患者，诺和诺德提供优惠券可将月费用减免至25美元。诺和诺德股价周一上涨5.2%，这可能得益于这家丹麦制药商在与肥胖药物市场另一主导者礼来的长期竞争中获得的首发优势。在诺和诺德的三期临床试验中，服用最高剂量Wegovy口服药的患者平均减重达17%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/dc46a35a40167e1ea8ec45d62fa07e24","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/dc46a35a40167e1ea8ec45d62fa07e24"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","LLY","NVO"],"gpt_icon":0},{"id":"1163752901","title":"“圣诞节可以收礼12天”？2026年这12只股票可作节日佳礼","url":"https://stock-news.laohu8.com/highlight/detail?id=1163752901","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163752901?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:29","pubTimestamp":1766647746,"startTime":"0","endTime":"0","summary":"特斯拉被认为是“美股七巨头”中最“顽皮”的一只股票，仅有45%的分析师给予其“买入”评级，且平均目标价低于当前股价。相比之下，罗素1000指数成分股的平均“买入”评级比例目前约为58%。大型成长股大幅上涨，就像拆开一份期盼已久的圣诞礼物。在罗素1000指数中，只有大约5%的股票，其目标价明显低于当前交易价格。即便是逆向投资者，可能也未必认为这是一份最好的“礼物”。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1303599391ea8a5a388ca86bb9de75b3","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1303599391ea8a5a388ca86bb9de75b3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"13d44e8d649e7e968597cd411f47871e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUR","VKTX","TSLA","FRMI","AMZN","LOAR","MSFT","MSTR","ALK","QXO","NVDA","Q","RARE"],"gpt_icon":1},{"id":"2585611379","title":"Viking Therapeutics, Inc.盘中异动 临近收盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585611379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585611379?lang=zh_cn&edition=full","pubTime":"2025-11-21 04:47","pubTimestamp":1763671654,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日04时47分，Viking Therapeutics, Inc.股票出现异动，股价大幅下挫5.07%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。消息层面，截至04时47分，《H.C. Wainwright维持Viking Therapeutics买入评级，维持目标价102美元》资讯为影响Viking Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121044735a4afeba0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121044735a4afeba0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4599","BK4007","VKTX","BK4588","BK4539","LENZ"],"gpt_icon":0},{"id":"1160513193","title":"维京治疗公司在2025年肥胖周会上展示Vk2735肥胖项目的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1160513193","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160513193?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:06","pubTimestamp":1762430775,"startTime":"0","endTime":"0","summary":"维京治疗公司在2025年肥胖周会上展示了Vk2735肥胖项目的临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","VKTX","BK4599"],"gpt_icon":0},{"id":"1168925049","title":"Viking Therapeutics股价下跌3.8%，因竞争对手Eli Lilly的GLP-1药丸在糖尿病患者后期试验中显示减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168925049","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168925049?lang=zh_cn&edition=full","pubTime":"2025-08-26 21:49","pubTimestamp":1756216158,"startTime":"0","endTime":"0","summary":"Viking Therapeutics股价下跌3.8%，因竞争对手Eli Lilly的GLP-1药丸在糖尿病患者后期试验中显示减重效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VKTX","BK4139","BK4588","BK4599"],"gpt_icon":0},{"id":"2561457586","title":"高盛评Viking Therapeutics(VKTX.US)口服药物VK2735试验结果：疗效显著但耐受性存疑 更适用体重维持","url":"https://stock-news.laohu8.com/highlight/detail?id=2561457586","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561457586?lang=zh_cn&edition=full","pubTime":"2025-08-21 16:15","pubTimestamp":1755764136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛本周发布关于Viking Therapeutics近期试验结果的评论报告并提及对礼来的影响。近日，Viking Therapeutics宣布，其口服药物VK2735用于治疗肥胖症的Ⅱ期VENTURE口服给药试验达到主要终点，顶线结果积极。需注意的是，Viking Therapeutics设想患者先以VK2735每周皮下注射进行诱导治疗，以快速达到目标体重，随后可继续维持该方案，或转为每月皮下注射或每日口服方案以帮助维持体重。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0004091025.USD","LU1868837300.USD","BK4539","IE0002270589.USD","BK4007","BK4533","BK4588","LU2750360641.GBP","IE00B19Z3581.USD","LU1868836914.USD","IE00B19Z3B42.SGD","LU2237443382.USD","LU2471134796.USD","LU1894683348.USD","IE0034235188.USD","LU2471134952.CNY","LU0048573561.USD","LU2237443895.HKD","LU2471134879.HKD","LU2237443465.HKD","LU0106831901.USD","LU1868837136.USD","LU2237443549.SGD","BK4139","BK4127","LU1668664300.SGD","BK4504","LU2237438978.USD","LU1791807156.HKD","VKTX","LU0251142724.SGD","LU1868836757.USD","LU0061475181.USD","LU2237443622.USD","LU2471134523.USD","LU0251131958.USD","IE00BSNM7G36.USD","LU1868836591.USD","BK4585","LU2237443978.SGD","BK4516","LU2750360997.AUD","LU0742534661.SGD","BK4550","LU0096364046.USD","LU1894683264.USD","IE0004086264.USD","LENZ","IE00BFXG1179.USD","BK4599"],"gpt_icon":1},{"id":"1171424689","title":"异动解读 | 维京治疗公司股价盘中大涨5.05%，肥胖药物试验数据获得积极评价","url":"https://stock-news.laohu8.com/highlight/detail?id=1171424689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171424689?lang=zh_cn&edition=full","pubTime":"2025-08-20 21:35","pubTimestamp":1755696906,"startTime":"0","endTime":"0","summary":"8月20日，生物制药公司维京治疗公司股价在盘中大涨5.05%，引起投资者广泛关注。这一涨幅主要源于该公司最新公布的肥胖药物试验结果获得分析师积极评价。维京治疗公司的实验性减肥药VK2735在一项中期试验中表现出色，帮助患者减轻了12.2%的体重。值得注意的是，17家券商中有15家给予维京治疗公司\"买入\"评级，显示出华尔街对该公司的强烈信心。这一观点进一步增强了投资者对VK2735未来发展潜力的信心，推动了股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":1},{"id":"1160858455","title":"Viking Therapeutics减肥口服药试验结果公布后股价暴跌，但它并非孤例","url":"https://stock-news.laohu8.com/highlight/detail?id=1160858455","media":"老虎资讯综合","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160858455?lang=zh_cn&edition=full","pubTime":"2025-08-20 07:43","pubTimestamp":1755647036,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. 周二宣布，其口服减肥药物在临床试验中显示出疗效 —— 但与规模更大的竞争对手类似，该公司股价随即应声下挫。Viking 的股票在周二暴跌 42%。Viking 表示，其 VK2735 口服减重药物在 13 周治疗后，患者平均减重 12.2%，约 26.6 磅。在最高剂量组中，38% 的患者提前中止治疗，而安慰剂组也有 18% 提前退出。根据 S&P Global Market Intelligence 的会议纪要，Viking 首席执行官 Brian Lian 回应道：“我们注意到在之前的试验中，安慰剂组的停药率有所升高。”","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viking Therapeutics减肥口服药试验结果公布后股价暴跌，但它并非孤例","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"gpt_icon":0},{"id":"2560844145","title":"口服减肥药“翻车” ！Viking Therapeutics Inc.(VKTX.US)股价闪崩42% 空头一夜血赚5.21亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560844145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560844145?lang=zh_cn&edition=full","pubTime":"2025-08-20 07:18","pubTimestamp":1755645490,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，Viking Therapeutics Inc.创下史上最大股价跌幅，让做空该公司的交易员获得巨额收益，一举扭转了今年以来的亏损局面。根据S3 Partners LLC董事总经理Matthew Unterman的数据，这家生物技术公司周二股价暴跌42%，使空头单日实现5.21亿美元的账面收益。尽管如此，分析师仍看好Viking Therapeutics股价，近90%的分析师给予相当于“买入”的评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1331851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4585","BK4588","BK4539","VKTX","BK4139","BK4007","BK4599"],"gpt_icon":1},{"id":"2560519006","title":"福泰制药（VKTX）跌43.19%最近五个交易日迄今累计下跌41.18%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2560519006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560519006?lang=zh_cn&edition=full","pubTime":"2025-08-19 22:54","pubTimestamp":1755615291,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","LU1674673691.USD","LU2236285917.USD","SG9999001176.USD","LU0061475181.USD","IE00BZ9MQY76.HKD","VRTX","BK4533","LU0417517546.SGD","LU0109394709.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","IE00B19Z3581.USD","BK4532","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","LU0234570918.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU2237438978.USD","LU2417539215.USD","VKTX","IE00B2B36J28.USD","LU0432979614.USD","SG9999001176.SGD","BK4585","IE0002270589.USD","LU2362540622.SGD","LU2462157665.USD","SG9999013999.USD","LU0889565916.HKD","BK4588","LU1035775433.USD","LU1674673428.USD","BK4139","LU1093756325.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2362541273.HKD","LU0079474960.USD","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","LU1069344957.HKD","LU0256863811.USD","LU1093756168.USD","LU1778281490.HKD","BK4567","LU0823416689.USD"],"gpt_icon":0},{"id":"1131183701","title":"异动解读 | Viking Therapeutics盘中大跌40%，口服减肥药临床试验结果不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183701","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131183701?lang=zh_cn&edition=full","pubTime":"2025-08-19 21:33","pubTimestamp":1755610398,"startTime":"0","endTime":"0","summary":"8月19日周二，生物制药公司Viking Therapeutics 股价盘中大跌40.62%，引发市场广泛关注。此次暴跌主要源于该公司公布的口服减肥药VK2735中期临床试验结果不及预期。据公司声明，在为期13周的中期试验中，VK2735帮助患者最多减重12.2%。这一结果打击了投资者对Viking Therapeutics能够在竞争激烈的减肥药市场上与行业巨头礼来和诺和诺德抗衡的信心。相比之下，礼来公司最近公布的口服减肥药orforglipron在72周试验中实现了12.4%的减重效果，而诺和诺德的口服semaglutide在68周内达到了15%的减重率。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":1},{"id":"2560419481","title":"由于Viking Therapeutics(VKTX.US)旗下实验性口服减肥药的中期试验数据不及预期截至发稿该股周二美","url":"https://stock-news.laohu8.com/highlight/detail?id=2560419481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560419481?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:57","pubTimestamp":1755608270,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1868837300.USD","GLP","LU1868836591.USD","NVO","SG9999001176.USD","LU0316494557.USD","LU0106261372.USD","LU0114720955.EUR","LU0109394709.USD","LU2552382215.SGD","LU0882574055.USD","LU2237443895.HKD","BK4144","LU1291159041.SGD","BK4581","LU1093756325.SGD","LU2461242641.AUD","LU1988902786.USD","LU0097036916.USD","LU2491050154.USD","VKTX","SG9999015978.USD","LU2602419157.SGD","LU0385154629.USD","IE00BFTCPJ56.SGD","GIPR","LU0823434740.USD","LU1974910355.USD","LU0122379950.USD","LU0354030511.USD","LU2237438978.USD","LU1917777945.USD","LU2237443622.USD","LU2023250504.SGD","LU2265009873.SGD","161027","LLY","SG9999014914.USD","LENZ","LU1983299246.USD","LU2462157665.USD","LU2063271972.USD","LU0820561909.HKD","SG9999013999.USD","LU1720051017.SGD","LU2456880835.USD","LU2491050071.SGD","LU0882574139.USD","LU0943347566.SGD"],"gpt_icon":0},{"id":"2560191248","title":"美股异动｜公布口服肥胖症药物最新实验数据后，Viking Therapeutics盘前大跌超34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560191248","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560191248?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:56","pubTimestamp":1755608200,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4139","LENZ","BK4007","BK4539","BK4588","VKTX","BK4599"],"gpt_icon":0},{"id":"2560914521","title":"Viking(VKTX.US)盘前暴跌！口服减肥药VK2735中期试验结果不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2560914521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560914521?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:50","pubTimestamp":1755607814,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443382.USD","LU2461242641.AUD","IE00B4R5TH58.HKD","NVO","LU0289739699.SGD","LENZ","LU1069344957.HKD","LU2471134952.CNY","LU0471298694.HKD","IE00BJT1NW94.SGD","LU2361044865.SGD","LU2106854487.HKD","LU2602419157.SGD","GB00BDT5M118.USD","LU1868836914.USD","LU2462157665.USD","LU0820561909.HKD","LU2023250504.SGD","LLY","LU0114720955.EUR","IE00BKVL7J92.USD","GIPR","161027","GLP","LU0198837287.USD","LU0323591593.USD","VKTX","BK4599","LU1988902786.USD","LU2237443978.SGD","LU1023059063.AUD","BK4139","IE00B1BXHZ80.USD","LU2471134879.HKD","LU1035775433.USD","SG9999001176.USD","LU0708995401.HKD","LU0823434583.USD","LU2468319806.SGD","LU1232071149.USD","SG9999014914.USD","LU0471298777.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU1093756325.SGD","BK4144","LU2491049909.HKD","LU1127390331.HKD","SG9999015952.SGD"],"gpt_icon":0},{"id":"1157008689","title":"盘前异动｜Viking Therapeutics跌超30%，口服减肥药试验数据低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1157008689","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157008689?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:31","pubTimestamp":1755606697,"startTime":"0","endTime":"0","summary":"盘前异动 | $Viking(VKTX)$ Therapeutics跌超30%，消息方面：公司口服减肥药的研究试验数据不及预期。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","VKTX","BK4539","BK4585","BK4599","BK4588"],"gpt_icon":0},{"id":"2557787675","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大涨5.01%报37.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557787675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557787675?lang=zh_cn&edition=full","pubTime":"2025-08-08 22:33","pubTimestamp":1754663586,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日22时33分，Viking Therapeutics, Inc.股票出现波动，股价快速拉升5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.73%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808223307973bfbdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808223307973bfbdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4588","BK4139","BK4539","BK4585","BK4599","VKTX"],"gpt_icon":0},{"id":"2555029842","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555029842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555029842?lang=zh_cn&edition=full","pubTime":"2025-07-31 02:35","pubTimestamp":1753900519,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日02时35分，Viking Therapeutics, Inc.股票出现波动，股价大幅拉升5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.91%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731023520a6ca1c56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731023520a6ca1c56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","VKTX","BK4539","LENZ","BK4007","BK4139","BK4585","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0605},{"period":"1month","weight":-0.0501},{"period":"3month","weight":-0.0112},{"period":"6month","weight":0.0728},{"period":"1year","weight":0.0121},{"period":"ytd","weight":-0.0239}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.006947},{"month":2,"riseRate":0.5,"avgChangeRate":0.226268},{"month":3,"riseRate":0.3,"avgChangeRate":-0.034371},{"month":4,"riseRate":0.5,"avgChangeRate":0.019074},{"month":5,"riseRate":0.272727,"avgChangeRate":0.07927},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.022105},{"month":7,"riseRate":0.545455,"avgChangeRate":0.01621},{"month":8,"riseRate":0.454545,"avgChangeRate":0.012248},{"month":9,"riseRate":0.272727,"avgChangeRate":0.053956},{"month":10,"riseRate":0.363636,"avgChangeRate":0.052351},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.018186},{"month":12,"riseRate":0.545455,"avgChangeRate":0.143438}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}